Precision Biosciences Inc (DTIL) Stock Price, Quote & News

Company Profile

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with t...

Industry: Biotechnology

Sector: Healthcare

Phone: 919 314 5512

Fax: 480 393 5553

Website: precisionbiosciences.com

Address:

302 East Pettigrew St., Suite A-100, Durham, United States

Madchemist0827 Dec. 8 at 2:33 AM

$DTIL https://announcements.asx.com.au/asxpdf/20251208/pdf/06t1v891tmmvbn.pdf Imugene with clear pathway to pivotal and BLA for Azer-cel, minutes from FDA coming Tuesday Dec 9

0 · Reply

steven1x Dec. 7 at 10:43 PM

$DTIL AI missing anything ? https://copilot.microsoft.com/shares/CTszdtfdVVVt17A4auipf

0 · Reply

Orlandotrader Dec. 4 at 8:56 PM

$DTIL We are pleased to share the latest clinical results from ELIMINATE-B with the international hepatology community at Hep-DART 2025," said Dr. Cassie Gorsuch, Chief Scientific Officer of Precision BioSciences. "Chronic hepatitis B continues to impose a significant global disease burden, and current therapies fall short of addressing the underlying cause of viral persistence Presentation title: PBGENE-HBV, a first-in-class gene editing therapy for chronic hepatitis B, demonstrates safety and antiviral activity across three cohorts Date and time: Tuesday, December 9th, 4:45pm HST

0 · Reply

Impatient_Investor Dec. 4 at 6:25 AM

$DTIL scam company. Only failed or terminated partnerships so far. 3 terminated in the past 4 years, including the recent no result partnership with Novartis for sickle cell disease and beta thalassemia. Anticipating the fourth one for TGTX collaboration. Fraud company run by a fraud management.

0 · Reply

Impatient_Investor Dec. 3 at 7:30 PM

$DTIL tax loss selling will start from third week of december

0 · Reply

Impatient_Investor Dec. 3 at 7:46 AM

$DTIL Dear retailers, be careful with this scam company. They have joined hands with institutional cartels to loot retail investment. Expect a below $3.0 SP by end of december considering tax loss harvesting. Most of my predictions have become true unlike the paid pumper @Scrood_the_Pooch

0 · Reply

Impatient_Investor Dec. 2 at 8:03 AM

$DTIL a typical paid pumper post

0 · Reply

Impatient_Investor Dec. 2 at 8:02 AM

$DTIL sorry revising the PT considering the tax loss sellings in december.

0 · Reply

Scrood_the_Pooch Dec. 2 at 12:54 AM

$DTIL OK, break out the iEcure results:

0 · Reply

Impatient_Investor Dec. 1 at 7:58 PM

$DTIL

1 · Reply

Precision Biosciences: Still Swinging And Finally Drawing Blood

Nov 19, 2025, 7:01 AM EST - 18 days ago

Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025

Nov 11, 2025, 4:11 PM EST - 26 days ago

Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript

Nov 10, 2025, 6:12 PM EST - 27 days ago

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

Nov 10, 2025, 5:21 PM EST - 27 days ago

Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts

Nov 3, 2025, 7:01 AM EST - 4 weeks ago

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 31, 2025, 7:01 AM EDT - 5 weeks ago

Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025

Oct 14, 2025, 7:01 AM EDT - 7 weeks ago

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025

Oct 9, 2025, 7:01 AM EDT - 2 months ago

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases

Oct 7, 2025, 7:01 AM EDT - 2 months ago

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial

Sep 30, 2025, 7:01 AM EDT - 2 months ago

Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society

Sep 16, 2025, 5:52 AM EDT - 2 months ago

Precision BioSciences, Inc. (DTIL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 12, 2025, 7:01 AM EDT - 3 months ago

Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium

Sep 8, 2025, 7:01 AM EDT - 3 months ago

Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status

Aug 7, 2025, 11:13 AM EDT - 4 months ago

DTIL Revenue Drops 99%

Aug 7, 2025, 7:01 AM EDT - 4 months ago

Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 7:01 AM EDT - 4 months ago

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B

Aug 4, 2025, 7:01 AM EDT - 4 months ago

Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025

Jul 23, 2025, 7:01 AM EDT - 4 months ago

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Jul 16, 2025, 7:01 AM EDT - 5 months ago

Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic

Jun 25, 2025, 7:01 AM EDT - 5 months ago

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

May 15, 2025, 7:01 AM EDT - 7 months ago

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 4:30 PM EDT - 7 months ago

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 8, 2025, 7:01 AM EDT - 7 months ago

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

May 7, 2025, 7:01 AM EDT - 7 months ago

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

May 1, 2025, 7:01 AM EDT - 7 months ago

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Apr 29, 2025, 7:00 AM EDT - 7 months ago

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Apr 15, 2025, 7:01 AM EDT - 8 months ago

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Apr 1, 2025, 7:01 AM EDT - 8 months ago

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 7:01 AM EDT - 9 months ago

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Mar 21, 2025, 7:01 AM EDT - 9 months ago

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Mar 20, 2025, 7:01 AM EDT - 9 months ago

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Mar 19, 2025, 7:01 AM EDT - 9 months ago

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 17, 2025, 7:01 AM EDT - 9 months ago

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

Mar 12, 2025, 8:00 AM EDT - 9 months ago

iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting

Feb 24, 2025, 7:01 AM EST - 10 months ago

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 19, 2025, 2:27 PM EST - 10 months ago

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Feb 19, 2025, 7:01 AM EST - 10 months ago

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Jan 29, 2025, 7:01 AM EST - 11 months ago

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Jan 10, 2025, 2:18 PM EST - 11 months ago

Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst

Jan 9, 2025, 10:01 AM EST - 11 months ago

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Jan 9, 2025, 8:00 AM EST - 11 months ago

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Dec 18, 2024, 7:01 AM EST - 1 year ago

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

Nov 21, 2024, 7:01 AM EST - 1 year ago

Precision BioSciences to Participate in Upcoming November Investor Conferences

Nov 15, 2024, 7:00 AM EST - 1 year ago

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Nov 4, 2024, 7:01 AM EST - 1 year ago

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 29, 2024, 7:01 AM EDT - 1 year ago

Precision BioSciences to Report Third Quarter Results on November 4, 2024

Oct 28, 2024, 7:01 AM EDT - 1 year ago

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

Oct 24, 2024, 4:15 PM EDT - 1 year ago

Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress

Oct 24, 2024, 8:47 AM EDT - 1 year ago

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Madchemist0827 Dec. 8 at 2:33 AM

$DTIL https://announcements.asx.com.au/asxpdf/20251208/pdf/06t1v891tmmvbn.pdf Imugene with clear pathway to pivotal and BLA for Azer-cel, minutes from FDA coming Tuesday Dec 9

0 · Reply

steven1x Dec. 7 at 10:43 PM

$DTIL AI missing anything ? https://copilot.microsoft.com/shares/CTszdtfdVVVt17A4auipf

0 · Reply

Orlandotrader Dec. 4 at 8:56 PM

0 · Reply

Impatient_Investor Dec. 4 at 6:25 AM

0 · Reply

Impatient_Investor Dec. 3 at 7:30 PM

$DTIL tax loss selling will start from third week of december

0 · Reply

Impatient_Investor Dec. 3 at 7:46 AM

0 · Reply

Impatient_Investor Dec. 2 at 8:03 AM

$DTIL a typical paid pumper post

0 · Reply

Impatient_Investor Dec. 2 at 8:02 AM

$DTIL sorry revising the PT considering the tax loss sellings in december.

0 · Reply

Scrood_the_Pooch Dec. 2 at 12:54 AM

$DTIL OK, break out the iEcure results:

0 · Reply

Impatient_Investor Dec. 1 at 7:58 PM

$DTIL

1 · Reply

thebenchwarmers Dec. 1 at 7:45 PM

$DTIL https://www.proactiveinvestors.com.au/companies/news/1083461/imugene-lifts-response-rate-to-82-in-phase-1b-trial-of-azer-cel-car-t-therapy-1083461.html?rel=scroll

0 · Reply

Impatient_Investor Nov. 29 at 7:33 AM

$DTIL

0 · Reply

Impatient_Investor Nov. 28 at 11:28 PM

$DTIL three failed or terminated partnerships in the last three years. The fourth one I am foreseeing is TGTX partnership. This is just a scam company. See what they had done with the recent offering. SP touched $8.8 but they announced offering after the SP fell to lower 6's just to favor some of their institutional investors in return for something unknown to us.

0 · Reply

Impatient_Investor Nov. 28 at 5:09 PM

$DTIL Institutions and insiders both dumped their holdings to retailers at a higher price just before the offering. Scam partnership.

1 · Reply

Impatient_Investor Nov. 28 at 5:06 PM

$DTIL Management aka daylight robbers looting millions as salaries.

0 · Reply

JVDBNL Nov. 28 at 4:21 PM

$DTIL Fyi: https://clinicaltrials.gov/study/NCT07254208

0 · Reply

Scrood_the_Pooch Nov. 27 at 3:36 PM

$DTIL https://www.forbes.com.au/covers/innovation/the-australian-biotechs-racing-toward-the-next-billion-dollar-cancer-drug/

0 · Reply

Impatient_Investor Nov. 26 at 9:37 PM

$DTIL scam company run by a scam management. Dont throw your money in this garbage

0 · Reply

Impatient_Investor Nov. 26 at 6:59 AM

$DTIL stay away dear retailers. Only failed partnerships so far. Institutions are doing pump and dump.

0 · Reply

Impatient_Investor Nov. 26 at 4:44 AM

$DTIL fraud management run company.

0 · Reply

JoshThe3rd Nov. 25 at 11:31 PM

$DTIL Trading at cash value fully diluted. 75M offering with good life sci investors. If data hits then this is going 100.00+. I like the r/r at these levels for a long swing.

1 · Reply

thebenchwarmers Nov. 25 at 1:42 PM

$DTIL This is in regards to Capricors drug in Ph 3. Lets hope PGGENE-DMD can reach all these targeted tissues when clinical trials begin. 🫰

0 · Reply

Market Cap	66.55M
Revenue (ttm)	68.70M
Net Income (ttm)	7.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	10.44%
Debt to Equity Ratio	1.35

Volume	183,500
Avg Vol	198,052
Day's Range	N/A - N/A
Shares Out	13.26M
Stochastic %K	38%
Beta	1.11
Analysts	Strong Sell
Price Target	$32.50